Ribomic Inc. (4591.T)
JPY 88.0
(-1.12%)
JPY 88.0
(-1.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.01 Billion JPY | 40.21% |
| 2022 | -1.78 Billion JPY | -5.8% |
| 2021 | -1.73 Billion JPY | -39.13% |
| 2020 | -1.21 Billion JPY | -35.11% |
| 2019 | -897 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -254.5 Million JPY | 10.54% |
| 2023 Q1 | -338.47 Million JPY | -24.99% |
| 2023 Q2 | -243.87 Million JPY | 27.95% |
| 2023 Q4 | -246.66 Million JPY | 0.59% |
| 2023 Q3 | -248.13 Million JPY | -1.75% |
| 2023 FY | - JPY | 40.21% |
| 2022 Q3 | -584.79 Million JPY | -97.93% |
| 2022 FY | - JPY | -5.8% |
| 2022 Q4 | -270.8 Million JPY | 53.69% |
| 2022 Q2 | -295.45 Million JPY | 0.0% |
| 2021 FY | - JPY | -39.13% |
| 2020 FY | - JPY | -35.11% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 205.68% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -107.429% |
| GNI Group Ltd. | 14.48 Billion JPY | 106.988% |
| Linical Co., Ltd. | 1.24 Billion JPY | 181.182% |
| Trans Genic Inc. | 240.95 Million JPY | 520.219% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 25.322% |
| Soiken Holdings Inc. | -583.2 Million JPY | -73.614% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -67.889% |
| AnGes, Inc. | -8.86 Billion JPY | 88.572% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 21.234% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 86.315% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 890.375% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -17.326% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 7.259% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1987.245% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -30.549% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -805.65% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 16.44% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 26.672% |
| PeptiDream Inc. | 7.37 Billion JPY | 113.727% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 47.529% |
| SanBio Company Limited | -4.52 Billion JPY | 77.624% |
| Healios K.K. | -3 Billion JPY | 66.328% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 13.146% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 27.317% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 27.78% |
| StemRIM | -2.03 Billion JPY | 50.171% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 177.503% |
| FunPep Company Limited | -952 Million JPY | -6.358% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -13.925% |
| Stella Pharma Corporation | -723.85 Million JPY | -39.88% |
| TMS Co., Ltd. | -937 Million JPY | -8.06% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -30.583% |
| Cuorips Inc. | -518 Million JPY | -95.468% |
| K Pharma,Inc. | 366.05 Million JPY | 376.603% |
| Takara Bio Inc. | 8.02 Billion JPY | 112.619% |
| ReproCELL Incorporated | 8.24 Million JPY | 12380.485% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1251.409% |
| StemCell Institute Inc. | 534.35 Million JPY | 289.486% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 513.59% |
| CellSeed Inc. | -836.51 Million JPY | -21.041% |